@article{oai:nagoya.repo.nii.ac.jp:00023914,
 author = {Kuramitsu, Shunichiro and Yamamichi, Akane and Ohka, Fumiharu and Motomura, Kazuya and Hara, Masahito and Natsume, Atsushi},
 issue = {12},
 journal = {Immunotherapy},
 month = {Dec},
 note = {Patients with glioblastoma have a very poor prognosis. Adoptive cellular therapy (ACT) is defined as the collection of circulating or tumor-infiltrating lymphocytes, their selection, modification, expansion and activation, and their re-administration to patients in order to induce antitumor activity. Although various ACTs have been attempted, most failed to improve the outcome. Immune checkpoint blockade antibodies and T cell engineering with tumor-specific chimeric antigen receptors suggest the emergence of a new era of immunotherapy. Here, we summarize approaches with ACTs using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to develop these therapies. The mechanisms by which gliomas modulate and evade the immune system are also discussed.},
 pages = {1393--1404},
 title = {Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities},
 volume = {8},
 year = {2016}
}